Deals
Deal activity by volume related to cybersecurity increased by 100% year-on-year in 2022 in the pharmaceutical industry
Credit: Bert van Dijk/Getty images.
Powered by
Analysis of the key themes driving deal activity reveals that cybersecurity accounted for 29 pharmaceutical deals between 2018 and 2022, worth a total value of $1,837m, according to GlobalData’s Deals database covering mergers and acquisitions, private equity, venture financing, equity offerings and partnerships. The $1,811m licensing agreement between Lantheus and POINT Biopharma was the largest disclosed deal in 2022, while the $2.2m venture financing raised by Humankind Ventures was the largest disclosed deal in 2021.
In volume terms, cybersecurity related deal activity increased by 100% year-on-year in 2022 and remained flat year-on-year in 2021.
Deal activity related to cybersecurity in the global pharmaceutical industry in the last five years
Top deals related to cybersecurity in the pharmaceutical industry in the last five years
Deal volume by deal type for cybersecurity related deals in the pharmaceutical industry in the last five years
Acquisitions and partnerships accounted for the highest number of deals in the last five years, with 7 deals each, followed by venture financing (4 deals), and licensing agreements (4 deals).
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Deals database provides comprehensive coverage across industries tracking market activity of global mergers & acquisitions, including asset acquisitions/divestments; private equity deals (PE); venture finance deals (VC); equity offerings, including IPOs, follow-on offerings, and private placements; debt offerings, including private placements, ESG bonds and loans; partnerships; and licensing agreements.
This analysis considers only announced and completed deals from the GlobalData financial deals database and excludes all terminated and rumored deals.
